| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Aminoglycosides Linked to Sensorineural Hearing Loss in Children With Cystic Fibrosis ALEXANDRIA, Va -- July 1, 2009 -- An otherwise effective treatment for cystic fibrosis places paediatric patients at a high risk of sensorineural hearing loss, according to a study published in the July edition of Otolaryngology-Head and Neck Surgery. Children with cystic fibrosis who receive systemic or intranasal aminoglycosides have a higher risk of sensorineural hearing loss. Alan G. Cheng, MD, Children’s Hospital of Boston, Boston, Massachusetts, and colleagues reviewed the medical records of children with cystic fibrosis (CF) that were treated at the Children’s Hospital of Boston over a 13 year period. They found that 7 of 50 (14%) patients with cystic fibrosis suffered from sensorineural hearing loss. Of that group, 43% of those that had received aminoglycosides intravenously had received more than 10 courses of the treatment; patients who were treated more than 5 times with nasal irrigation of aminoglycosides were also at risk of sensorineural hearing loss. Because patients with cystic fibrosis are prone to suffer from infections of the pulmonary and sinonasal systems, aminoglycosides are commonly administered. The treatment is considered so effective that it outweighs the well-known side-effects, which include hair cell loss, and thus hearing loss. The authors contend that patients with cystic fibrosis should have routine hearing evaluations that specifically target the detection of sensorineural hearing loss, especially when repeated courses of systemic or intranasal aminoglycosides have be used in treatment. They also noted that further investigation through a prospective study is warranted in order to replicate these results. SOURCE: Otolaryngology-Head and Neck Surgery
|